2012 Annual Report - Sentara.com

Hematology/Oncology Cancer Program
Multidisciplinary Approach
The Sentara Cancer Network adopts a multidisciplinary
approach to the diagnosis and treatment of leukemia
and lymphoma, as well as other blood disorders. The
Hematology/Oncology team consists of highly skilled
physician leaders and health care specialists who work
together to deliver the best possible outcome, and are
committed to patient comfort and recovery.
The dedicated Hematology/Oncology team meets
bi-weekly to review and discuss each patient’s case
and recommends the most appropriate treatments.
Hematopathology Advances
The hematopathology services of the Sentara Cancer
Network continue to make advances. Expanded
laboratory services now include Flow Cytometry,
Fluorescence in Situ Hybridization, Cytogenetics,
Immunohistochemistry, and Molecular Labs.
A sustained year-over-year growth in referred cases
is a testament to the clinical expertise and commitment
to high quality. In 2012, the projected number of
referred cases is:
n 1,007 Mone Marrow
Innovation and Technology
The Sentara Cancer Network Hematology/
Oncology cancer program offers innovative
technologies, methods and standards. Team
members frequently collaborate with Eastern
Virginia Medical School and Virginia Oncology
Associates on case reports and full clinicopathologic
research projects, demonstrating
a continued commitment to medical student/
resident education and translational research.
Other recent accomplishments include:
n Improvements and standardization
of coagulation lab testing
n Standardization of pathologic work up and
clinical care of patients, applying current
recommended guidelines
n 3,191 Flow
n 2,904 Fluorescence in Situ Hybridization
n 1,491 Marrow Cytogenetic
n 591 Constitutional Cytogenetic
22 Sentara Cancer Network 2012 Annual Report